Hikma Pharmaceuticals in the news
High-quality accessible medicines
Tamtam found 13 recent articles about Hikma Pharmaceuticals.
- Hikma stock heads into the open after a modest gain
Hikma's stock rose 0.7% on September 15, 2026, closing at GBP 19.18 on the London Stock Exchange, outperforming the FTSE 100.
- What Does Hikma Pharmaceuticals' (LSE:HIK) Dividend Mean For UK Holders?
Hikma Pharmaceuticals will pay an interim dividend on September 17, 2026, declared in US dollars, reflecting its strong US market presence in generics and injectables.
- Hikma Pharmaceuticals climbs Friday, outperforms market
Hikma Pharmaceuticals PLC shares gained 2.20% on Friday, outperforming the broader market.
- A needle-free epinephrine spray is under review in the US, Europe and UK
Hikma Pharmaceuticals' investigational needle-free epinephrine nasal spray for anaphylaxis is currently undergoing regulatory review in the US, Europe, and the UK, with additional filings in Canada and planned global submissions.
- Hikma advances its epinephrine nasal spray with multi-market regulatory filings
Hikma Pharmaceuticals' epinephrine nasal spray for anaphylaxis is undergoing regulatory review in multiple markets including the US, Europe, and the UK.
- Hikma Pharmaceuticals (LSE:HIK) Stock Fair Value Edges Higher After Bullish Analyst Targets
Hikma Pharmaceuticals' stock fair value and analyst price targets have increased, driven by positive sentiment from firms like Citi and Berenberg, though some risks related to optimistic assumptions are noted.
- ii view: Hikma keeps a healthy pulse with solid first half
Hikma Pharmaceuticals experienced a solid first half in 2026 with increased revenue and profit, maintaining its full-year guidance despite rising costs and market challenges.
- Hikma Pharmaceuticals rallies on improving trends
Hikma Pharmaceuticals' shares rallied due to improved performance in branded medicines and increased investment in R&D.
- Hikma Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Hikma Pharmaceuticals' global employee count is projected to reach 9,616 by March 2026, an 11.8% increase from 2023.
- Rep. Cockley Applauds Hikma Pharmaceuticals Expansion, Investment in Columbus Workforce | Republican News
Hikma Pharmaceuticals is investing $216M to expand its Columbus, Ohio manufacturing operations, creating 50 new jobs and reinforcing the region's pharmaceutical leadership.
- Skinny labelling after Hikma v Amarin: active inducement in the US Supreme Court (via Passle)
The US Supreme Court sided with Hikma Pharmaceuticals, ruling that Amarin Pharma failed to prove Hikma actively induced infringement with its skinny-labeled generic drug.
- Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Hikma Pharmaceuticals is expanding its Ohio manufacturing operations with a $267 million investment, creating 350 jobs in Columbus and Bedford to boost generic medicine production.
- Justices poised to protect generics manufacturers from liability for decisions of pharmacists about prescribing their products
The Supreme Court appears poised to rule in favor of Hikma Pharmaceuticals, indicating that generic drug manufacturers are not liable for pharmacists' patent-infringing dispensing decisions based on the evidence presented.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Hikma Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies